MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has scheduled its fourth quarter and full year 2024 financial results release for March 18th, 2025, before market opening.
The company will host a conference call and webcast at 8:30 a.m. ET on the same day, featuring a corporate update and discussion of financial results. Investors can access the call via phone at 646-307-1963 (New York) or 800-715-9871 (USA & Canada) using Conference ID 8023784, or through the company's investor relations website.
MiNK Therapeutics (NASDAQ: INKT), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie cellulari allogeniche, pronte all'uso, a base di cellule T natural killer invarianti (iNKT), ha programmato la pubblicazione dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per il 18 marzo 2025, prima dell'apertura del mercato.
La società ospiterà una conferenza telefonica e un webcast alle 8:30 a.m. ET nello stesso giorno, con un aggiornamento aziendale e una discussione sui risultati finanziari. Gli investitori possono accedere alla chiamata telefonicamente al numero 646-307-1963 (New York) o 800-715-9871 (USA e Canada) utilizzando l'ID conferenza 8023784, oppure attraverso il sito web delle relazioni con gli investitori della società.
MiNK Therapeutics (NASDAQ: INKT), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias con células T natural killer invariantes (iNKT) alogénicas y listas para usar, ha programado la publicación de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 18 de marzo de 2025, antes de la apertura del mercado.
La compañía llevará a cabo una conferencia telefónica y un webcast a las 8:30 a.m. ET el mismo día, que incluirá una actualización corporativa y una discusión sobre los resultados financieros. Los inversores pueden acceder a la llamada por teléfono al 646-307-1963 (Nueva York) o 800-715-9871 (EE.UU. y Canadá) utilizando el ID de conferencia 8023784, o a través del sitio web de relaciones con inversores de la empresa.
MiNK Therapeutics (NASDAQ: INKT)는 동종의, 즉시 사용 가능한 불변 자연 살해 T(iNKT) 세포 치료제를 개발하는 데 집중하는 임상 단계의 생명공학 회사로, 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 18일 시장 개장 전에 예정하고 있습니다.
회사는 같은 날 오전 8시 30분 ET에 기업 업데이트 및 재무 결과 논의를 포함하는 컨퍼런스 콜 및 웹캐스트를 개최할 예정입니다. 투자자는 646-307-1963(뉴욕) 또는 800-715-9871(미국 및 캐나다)로 전화하여 회의 ID 8023784를 사용하여 전화를 통해 참여하거나 회사의 투자자 관계 웹사이트를 통해 접속할 수 있습니다.
MiNK Therapeutics (NASDAQ: INKT), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies cellulaires à base de cellules T natural killer invariantes (iNKT) allogènes et prêtes à l'emploi, a prévu la publication de ses résultats financiers du quatrième trimestre et de l'année entière 2024 pour le 18 mars 2025, avant l'ouverture du marché.
L'entreprise organisera une conférence téléphonique et un webcast à 8h30 ET le même jour, comprenant une mise à jour de l'entreprise et une discussion sur les résultats financiers. Les investisseurs peuvent accéder à l'appel par téléphone au 646-307-1963 (New York) ou 800-715-9871 (États-Unis et Canada) en utilisant l'ID de conférence 8023784, ou via le site web des relations investisseurs de l'entreprise.
MiNK Therapeutics (NASDAQ: INKT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von allogenen, gebrauchsfertigen, invarianten natürlichen Killer-T (iNKT) Zelltherapien konzentriert, hat die Veröffentlichung seiner finanziellen Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 für den 18. März 2025, vor der Markteröffnung, angesetzt.
Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, in dem ein Unternehmensupdate und eine Diskussion der finanziellen Ergebnisse stattfinden. Investoren können die Konferenz telefonisch unter 646-307-1963 (New York) oder 800-715-9871 (USA & Kanada) mit der Konferenz-ID 8023784 oder über die Investor-Relations-Website des Unternehmens erreichen.
- None.
- None.
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 18th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
Conference Call
Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada)
Conference ID: 8023784
Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/s9hd6k7m/.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
Media Contact
781-674-4428
communications@minktherapeutics.com 
FAQ
When will MiNK Therapeutics (INKT) release its Q4 and full year 2024 earnings?
How can investors join MiNK Therapeutics' (INKT) Q4 2024 earnings call?
What type of cell therapies is MiNK Therapeutics (INKT) developing?
Where can I access the replay of INKT's Q4 2024 earnings webcast?
